| Literature DB >> 29066511 |
Stephanie Rossnagl1,2, Hiba Ghura1,2, Christopher Groth1,2, Eva Altrock1,2, Franz Jakob3, Sarah Schott4, Pauline Wimberger5, Theresa Link5, Jan Dominik Kuhlmann5, Arnulf Stenzl6, Jörg Hennenlotter6, Tilmann Todenhöfer6, Markus Rojewski7, Karen Bieback8, Inaam A Nakchbandi9,2.
Abstract
Breast and prostate cancer cells home to the bone marrow, where they presumably hijack the hematopoietic stem cell niche. We characterize here the elusive premetastatic niche by examining the role of mesenchymal stromal cells (MSC) in cancer cell homing. Decreasing the number of MSC pharmacologically enhanced cancer cell homing to the bone marrow in mice. In contrast, increasing the number of these MSCs by various interventions including G-CSF administration diminished cancer cell homing. The MSC subpopulation that correlated best with cancer cells expressed stem, endothelial, and pericytic cell markers, suggesting these cells represent an undifferentiated component of the niche with vascular commitment. In humans, a MSC subpopulation carrying markers for endothelial and pericytic cells was lower in the presence of cytokeratin+ cells in bone marrow. Taken together, our data show that a subpopulation of MSC with both endothelial and pericytic cell surface markers suppresses the homing of cancer cells to the bone marrow. Similar to the presence of cytokeratin+ cells in the bone marrow, this MSC subpopulation could prove useful in determining the risk of metastatic disease, and its manipulation might offer a new possibility for diminishing bone metastasis formation.Significance: These findings establish an inverse relationship between a subpopulation of mesenchymal stromal cells and cancer cells in the bone marrow. Cancer Res; 78(1); 129-42. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29066511 DOI: 10.1158/0008-5472.CAN-16-3507
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701